secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2023-05-16T23:59:59+00:00
Accession:  0001193125-23-146067
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears CABA-201 IND for Phase 1/2 myositis study; DesCAARTes updates provided
--------------------------------------------------------------------------------

- FDA cleared second IND for CABA-201 (CD19-CAR T) for Phase 1/2 trial in active myositis (DM, ASyS, IMNM) at 1x10^6 cells/kg dose.
- Company plans to enroll 18 patients in three parallel cohorts (6 each) for dermatomyositis, anti-synthetase syndrome, and immune-mediated necrotizing myopathy.
- DesCAARTes trial: modest persistence increase in first two patients in IVIg+Cy combination cohort; new fludarabine+IVIg+Cy cohort to be initiated.
- MusCAARTes study timelines being evaluated based on emerging DesCAARTes data.
- Myositis subtypes targeted affect ~66,000 patients in the US; current treatments often refractory.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523146067/0001193125-23-146067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523146067/d492544d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-146067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer